--- title: "Wall Street Zen Upgrades Adlai Nortye (NASDAQ:ANL) to Hold" type: "News" locale: "en" url: "https://longbridge.com/en/news/278205537.md" description: "Wall Street Zen has upgraded Adlai Nortye (NASDAQ:ANL) to a \"hold\" rating. Other analysts have mixed views, with HC Wainwright raising it to \"buy\" with a $16.00 price target, while Weiss Ratings maintained a \"sell\" rating. Currently, Adlai Nortye's stock is down 3.6%, trading at $8.91, with a consensus price target of $16.00. The company specializes in fine chemicals, particularly amino acids, and has a twelve-month price range of $0.88 to $12.09." datetime: "2026-03-07T08:19:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278205537.md) - [en](https://longbridge.com/en/news/278205537.md) - [zh-HK](https://longbridge.com/zh-HK/news/278205537.md) --- # Wall Street Zen Upgrades Adlai Nortye (NASDAQ:ANL) to Hold Adlai Nortye (NASDAQ:ANL - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "hold" rating in a research note issued on Saturday. Other analysts have also issued reports about the company. HC Wainwright raised Adlai Nortye from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research note on Friday, February 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Adlai Nortye in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Adlai Nortye has an average rating of "Hold" and a consensus price target of $16.00. **View Our Latest Stock Analysis on ANL** ## Adlai Nortye Stock Down 3.6% NASDAQ:ANL opened at $8.91 on Friday. The stock's 50-day simple moving average is $5.93 and its 200 day simple moving average is $3.09. Adlai Nortye has a twelve month low of $0.88 and a twelve month high of $12.09. ## About Adlai Nortye (Get Free Report) Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives. Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes. The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control. ## Read More - Five stocks we like better than Adlai Nortye - The gold chart Wall Street is terrified of… - America’s 1776 happening again - What a Former CIA Agent Knows About the Coming Collapse - Unlocked: Elon Musk’s Next Big IPO - Elon Musk already made me a “wealthy man” _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Adlai Nortye Right Now? Before you consider Adlai Nortye, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list. While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ANL.US](https://longbridge.com/en/quote/ANL.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)